SPRO
Spero Therapeutics, Inc. NASDAQ Listed Nov 2, 2017$2.51
Mkt Cap $145.3M
52w Low $0.57
73.2% of range
52w High $3.22
50d MA $2.51
200d MA $2.31
P/E (TTM)
16.5x
EV/EBITDA
-3881.6x
P/B
2.4x
Debt/Equity
0.1x
ROE
14.5%
P/FCF
-10.3x
RSI (14)
—
ATR (14)
—
Beta
1.45
50d MA
$2.51
200d MA
$2.31
Avg Volume
377.9K
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
675 Massachusetts Avenue · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.20 | 0.53 | +365.0% | 2.37 | -3.0% | -1.7% | -5.5% | -1.3% | +3.4% | +2.5% | — |
| Nov 13, 2025 | AMC | -0.25 | -0.13 | +48.0% | 2.44 | -2.0% | -1.2% | -0.4% | +1.2% | -2.5% | -7.4% | — |
| Aug 12, 2025 | AMC | -0.38 | -0.03 | +92.1% | 2.36 | -8.9% | -17.8% | -16.1% | -19.1% | -19.1% | -22.0% | — |
| May 13, 2025 | AMC | -0.55 | -0.25 | +54.5% | 0.69 | +1.4% | -5.8% | -5.6% | -5.7% | -0.1% | -1.4% | — |
| Mar 27, 2025 | AMC | -0.35 | -0.38 | -8.6% | 0.86 | -1.2% | -10.9% | -16.3% | -19.3% | -17.9% | -27.5% | — |
| Nov 14, 2024 | AMC | -0.27 | -0.32 | -18.5% | 1.25 | +0.0% | -5.6% | -8.8% | -7.2% | -4.0% | -4.8% | — |
| Aug 5, 2024 | AMC | -0.35 | -0.33 | +5.7% | 1.34 | +3.0% | -5.2% | -8.2% | -6.0% | -4.5% | -3.7% | — |
| May 15, 2024 | AMC | -0.07 | -0.24 | -242.9% | 1.62 | -1.2% | -3.1% | -1.9% | -3.7% | -6.8% | -6.8% | — |
| Mar 13, 2024 | AMC | -0.10 | 0.96 | +1060.0% | 1.66 | +10.2% | +4.8% | +7.8% | +4.2% | +7.2% | +6.0% | — |
| Nov 13, 2023 | AMC | -0.15 | 0.02 | +113.3% | 1.11 | +2.7% | -1.8% | +2.7% | +4.5% | +7.2% | +10.8% | — |
| Aug 10, 2023 | AMC | -0.29 | -0.23 | +20.7% | 1.45 | +1.4% | -3.4% | -5.5% | -6.9% | -9.7% | -7.6% | — |
| May 11, 2023 | AMC | -0.35 | -0.25 | +28.6% | 1.92 | -1.0% | -3.6% | -2.6% | -6.8% | -5.2% | -6.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.85 | -1.2% | +1.2% | -0.4% | -6.6% | -12.4% | +2.0% |
| Dec 20 | Evercore ISI | Downgrade | Outperform → In Line | — | $1.00 | $0.99 | -0.8% | -4.3% | -7.5% | -6.1% | -5.4% | +3.2% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.14 | $1.13 | -0.9% | -0.9% | +1.8% | +3.5% | +1.8% | +2.6% |
| Nov 18 | TD Cowen | Downgrade | Buy → Hold | — | $1.18 | $1.20 | +1.7% | -3.4% | -1.7% | +1.7% | +0.8% | -1.7% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.18 | $1.16 | -1.7% | +9.3% | +11.0% | +11.0% | +11.0% | +11.9% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.33 | +1.5% | -1.5% | -0.8% | -0.8% | -5.3% | -5.3% |
| Aug 6 | TD Cowen | Upgrade | Hold → Buy | — | $1.34 | $1.38 | +3.0% | -5.2% | -8.2% | -6.0% | -4.5% | -3.7% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.34 | $1.38 | +3.0% | -5.2% | -8.2% | -6.0% | -4.5% | -3.7% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.62 | $1.60 | -1.2% | -3.1% | -1.9% | -3.7% | -6.8% | -6.8% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.79 | $1.70 | -5.0% | -3.4% | -0.6% | -1.7% | -3.4% | -2.2% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.11 | $1.14 | +2.7% | -1.8% | +2.7% | +4.5% | +7.2% | +10.8% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.52 | +0.0% | -5.9% | -9.2% | -11.8% | -10.5% | -12.5% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.41 | +0.7% | -2.1% | -3.6% | -6.4% | -4.3% | -8.6% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.63 | $1.62 | -0.6% | -6.7% | -5.5% | -7.4% | -7.4% | -8.0% |
| Jul 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.48 | $1.48 | +0.0% | -1.4% | -2.0% | -2.0% | -4.7% | -4.1% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | +3.3% | +7.3% | +7.3% | +13.2% | +13.9% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $2.00 | +1.5% | +6.1% | +2.5% | +4.1% | +0.0% | +1.5% |
| Sep 23 | Evercore ISI | Upgrade | In Line → Outperform | — | $2.20 | $2.27 | +3.2% | -10.5% | -5.0% | -8.2% | -6.8% | -10.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.78 | $0.78 | +0.0% | +15.9% | +14.9% | +37.2% | +32.1% | +26.0% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.37 | -0.7% | -3.6% | -10.9% | -13.0% | -13.0% | -10.1% |
| May 20 | Berenberg | Downgrade | Buy → Hold | — | $1.44 | $1.41 | -2.1% | -4.2% | -7.6% | -14.6% | -16.7% | -16.7% |
| May 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.71 | $1.77 | +3.5% | -3.5% | -15.8% | -15.8% | -19.3% | -22.2% |
| May 4 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $1.85 | $1.62 | -12.4% | -5.4% | -0.5% | +11.9% | +2.2% | -4.9% |
| May 4 | Evercore ISI | Downgrade | Outperform → In Line | — | $1.85 | $1.62 | -12.4% | -5.4% | -0.5% | +11.9% | +2.2% | -4.9% |
| Apr 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.11 | $6.02 | -1.5% | -6.9% | -2.6% | -3.4% | -10.5% | -10.3% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.38 | $8.72 | +4.1% | +1.7% | +3.2% | +0.7% | +0.2% | -2.7% |
| Oct 1 | Oppenheimer | Downgrade | Outperform → Perform | — | $18.41 | $17.57 | -4.6% | -4.7% | -1.8% | +2.0% | -6.0% | -7.1% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.75 | $18.65 | +5.1% | +5.9% | +6.8% | +5.1% | +1.4% | +2.5% |
| Dec 16 | Berenberg | Maintains | Buy → Buy | — | $17.40 | $17.87 | +2.7% | +5.5% | +6.5% | +1.7% | +9.2% | +25.0% |
| Nov 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.18 | $15.86 | +4.5% | +4.7% | +4.7% | +4.9% | +10.2% | +9.2% |
| Sep 29 | Evercore ISI | Maintains | Outperform → Outperform | — | $9.30 | $10.22 | +9.9% | +7.0% | +20.0% | +25.3% | +29.7% | +34.0% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.78 | $11.85 | +0.6% | +8.2% | +1.9% | -0.7% | -0.7% | +1.3% |
| Mar 17 | Stifel | Maintains | Buy → Buy | — | $5.27 | $5.60 | +6.3% | +28.8% | +17.5% | +24.3% | +10.2% | +12.5% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.71 | $10.88 | +1.6% | -2.0% | -0.1% | -1.3% | -1.7% | -2.1% |
| Nov 5 | H.C. Wainwright | Maintains | Buy → Buy | — | $10.71 | $10.88 | +1.6% | -2.0% | -0.1% | -1.3% | -1.7% | -2.1% |
| Sep 9 | Janney Capital | Maintains | Buy → Buy | — | $9.98 | $10.74 | +7.6% | +11.2% | +17.7% | +25.8% | +24.6% | +19.6% |
| Oct 16 | Bank of America | Downgrade | Neutral → Underperform | — | $9.76 | $9.33 | -4.4% | -12.8% | -12.0% | -12.5% | -12.7% | -13.8% |
| Oct 16 | BofA Securities | Downgrade | Neutral → Underperform | — | $9.76 | $9.33 | -4.4% | -12.8% | -12.0% | -12.5% | -12.7% | -13.8% |
| May 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $11.59 | $12.58 | +8.5% | +3.9% | -1.6% | +5.5% | +4.3% | +4.7% |
| Feb 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.97 | $12.08 | +0.9% | -0.8% | -3.4% | -6.4% | -16.5% | -16.8% |
| Nov 27 | Cowen & Co. | Maintains | Outperform → Outperform | — | $13.86 | $14.26 | +2.9% | +1.5% | -1.7% | -7.8% | -13.8% | -12.4% |
| Nov 27 | Stifel Nicolaus | Maintains | Buy → Buy | — | $13.86 | $14.26 | +2.9% | +1.5% | -1.7% | -7.8% | -13.8% | -12.4% |
| Nov 27 | Bank of America | Maintains | Neutral → Neutral | — | $13.86 | $14.26 | +2.9% | +1.5% | -1.7% | -7.8% | -13.8% | -12.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Rajavelu Esther | See Remarks | Sell | 25,240 | $2.51 | $63K | 986,851 | -0.79% | — |
Data updated apr 27, 2026 2:39am
· Source: massive.com